Dallas, TX: ReportsandReports announce Celgene Corporation: PharmaVitae Profile Market Research Report in its Store.
Browse complete Report at: http://www.reportsandreports.com/reports/8939-celgene-corporation-pharmavitae-profile.html
This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
• Benchmark Celgene’s performance against key rivals in the prescription pharmaceutical sector
• Understand how Revlimid will drive the company’s performance out to 2013
• See how the acquisition of Pharmion will affect Celgene’s strategy
• Table Of Contents
• ABOUT DATAMONITOR HEALTHCARE 2
• About the PharmaVitae team 2
• Chapter 1 About this profile 3
• PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 4
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
• Chapter 2 Executive summary 5
• Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Celgene: PharmaVitae forecasts at a glance 8
Strategic insight 9
Increase scale through M&A 9
Profit expansion post M&A 10
Revlimid remains central to Celgene’s performance to 2014 10
A focused player in an international market 12
A focused portfolio…. 12
for an international market 13
SWOT analysis 14
Strengths 14
Weaknesses 15
Opportunities 15
Threats 16
Table of Contents 17
Table of figures 19
• Chapter 3 Quarterly news update 20
• Product developments 20
Deals and alliances 22
Product deals 22
Technology deals 23
M&A activity 23
Company announcements 24
Future product milestones 24
• Chapter 4 Company introduction 25
• Key findings 25
Background 26
Key corporate developments 26
M&A history 28
Historical divestment generates capital 28
Minor acquisitions permit steady expansion 28
Pharmion acquisition is central to Celgene’s future growth 28
Gloucester Pharmaceuticals acquisition provides boost to launch portfolio 29
Current corporate structure 29
Pharmaceuticals 29
Collaborative agreements 29
Royalty revenue 29
• Chapter 5 Company sales 30
• Key findings 30
Prescription pharmaceutical sales and growth rate analysis, 2002-14 31
Product analysis 33
Product analysis, 2002-08 34
Product analysis, 2008-14 36
Therapy area analysis 39
Geographic analysis 41
Launch/core/expiry analysis 43
Explanation of launch/core/expiry analysis 43
Launch analysis, 2008-14 44
Core analysis, 2008-14 46
Expiry analysis, 2008-14 47
Launch/core/expiry configuration, 2008-14 48
Molecule type analysis 49
Externalization analysis 51
• Chapter 6 Company financials 53
• Key findings 53
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 54
Operating costs and profit analysis 56
Operating costs and profit analysis, 2002-08 57
Operating cost ratio and profit margin analysis, 2002-08 59
Operating cost ratio and profit margin analysis, 2008-14 60
Operating costs and profit analysis, 2008-14 61
• Chapter 7 Key products and competitors 62
• Key findings 62
Overview 63
Oncology 64
Revlimid 64
Overview 64
Sales forecast 65
What is Revlimid? 65
Revlimid indicated for MDS 65
Revlimid to file for MM front-line therapy 66
Competition from Millennium’s Velcade 66
Vidaza 67
Overview 67
Sales forecast 68
Pharmion acquisition brings together Vidaza, Revlimid and Thalomid 68
Generics forecast to enter US market in 2011 69
Dacogen EU trial failure to benefit Vidaza European market share 69
Actimid (CC-4047) 70
Overview 70
Sales forecast 71
What is Actimid? 71
Thalomid/Thalidomide Pharmion 72
Overview 72
Sales forecast 73
What is Thalomid? 73
Pharmion acquisition grants Celgene full rights to its formerly out-licensed Thalomid 74
Generic threat from Barr 74
Istodax 76
Overview 76
Sales forecast 77
Istodax gained via Gloucester Pharmaceuticals acquisition 77
Istodax is also in development for other cancer indications. 77
Amrubicin 78
Overview 78
Sales forecast 79
What is amrubicin? 79
Small cell lung cancer presents limited long-term growth potential 79
Amrubicin will need to show clinical advantages over Hycamtin 80
Patent protection is unclear and reliant on exclusivity period 80
• Chapter 8 Appendix 81
• R&D pipeline 81
References 82
Abbreviations 82
Exchange rates 83
About Datamonitor 84
About Datamonitor Healthcare 84
Datamonitor consulting 84
Disclaimer 86
ABBREVIATIONS
Browse all : Healthcare Market Research Reports
http://www.reportsandreports.com/cat/healthcare-market-research.html
Browse all : Datamonitor Market Research Reports
http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html
Browse all Newly Published Market Research Reports
http://www.reportsandreports.com/LatestReport.aspx
Original Source : PharmaV itae Market
http://www.reportsandreports.com/reports/8939-celgene-corporation-pharmavitae- profile.html
Buy Now : Market Research Report
http://www.reportsandreports.com/
Related Reports:
Browse all : Celgene Corporation-Detailed Product Pipeline
http://www.reportsandreports.com/reports/3762-celgene-corporation-detailed-product-pipeline.html
Browse all : Celgene Corporation-Deals & Alliances Report
http://www.reportsandreports.com/reports/4204-celgene-corporation-deals-alliances-report.html
Browse all : Celgene Corporation-Therapeutic Competitors
http://www.reportsandreports.com/reports/3328-celgene-corporation-therapeutic-competitors.html
Browse all : Celgene Corporation – SWOT Analysis
http://www.reportsandreports.com/reports/1995-celgene-corporation-swot-analysis.html
Browse all : Genzyme Corporation: PharmaVitae Profile
http://www.reportsandreports.com/reports/8030-genzyme-corporation-pharmavitae-profile.html
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
